Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The N-methyl-D-aspartate receptor (NMDAR) C-terminal domain–PDZ scaffold protein interface is a specialized protein-protein interaction (PPI) site that anchors NMDARs to the postsynaptic density and couples them to intracellular signaling pathways [1.1.2, 1.4.1]. The interface primarily involves the interaction between the C-terminal PDZ-binding motifs of NMDAR subunits, such as GluN2B, and the PDZ domains of scaffolding proteins like Postsynaptic Density Protein 95 (PSD-95) [1.1.3, 1.4.3]. This coupling is essential for physiological processes like synaptic plasticity, learning, and memory, but it also facilitates the recruitment of neuronal nitric oxide synthase (nNOS) [1.1.1, 1.5.2]. Under conditions of excitotoxicity, such as during an ischemic stroke, excessive NMDAR activation leads to overproduction of nitric oxide through this complex, causing neuronal death [1.2.2, 1.3.1]. Therapeutic agents like Nerinetide (NA-1) are designed to competitively inhibit this interface, thereby uncoupling NMDARs from toxic downstream signaling without blocking the receptor's essential ionotropic functions [1.2.3, 1.4.4]. This approach offers a neuroprotective strategy that avoids the severe side effects typically associated with direct NMDAR antagonists [1.3.4, 1.5.1]. Clinical development of inhibitors targeting this interface has primarily focused on acute ischemic stroke, where preserving neuronal viability during the reperfusion phase is critical [1.2.5].
Competitive inhibition of the protein-protein interaction between the NMDAR C-terminal PDZ-binding motif and the PDZ domains of scaffold proteins (primarily PSD-95). This uncouples the receptor from downstream neurotoxic signaling pathways, such as the activation of neuronal nitric oxide synthase (nNOS), without inhibiting the physiological ionotropic function of the NMDAR.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on N-methyl-D-aspartate receptor C-terminal domain–PDZ scaffold protein interface (NMDAR-PDZ interface).